The Yorkshire & Humber Academic Health Science Network (AHSN) is proud to announce that its innovative Faecal Calprotectin Pathway has been shortlisted for a prestigious HSJ Award.
The new Faecal Calprotectin Pathway, which helps GPs make the difficult discrimination between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), was developed by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust.
The Yorkshire & Humber AHSN has successfully supported the rollout of the new pathway across seven Clinical Commissioning Groups (CCGs) and 198 GP practices. A further nine CCGs are fully engaged with implementation plans in place and the new pathway is influencing national clinical guidelines.
IBS affects 10-20 per cent of the population, half of whom will consult their GP with 79,000 new cases being diagnosed each year. IBD occurs much less commonly, being seen three per cent of the time.
As distinguishing IBS from IBD is difficult, as many as 19 out of 20 patients are unnecessarily referred to secondary care, which often includes an invasive colonoscopy.
Use of the new pathway in the region has resulted in a 40-57 per cent reduction in new hospital outpatients’ appointments and a 21-50 per cent reduction in colonoscopies. There are projected savings to each CCG of £68,000-£100,000 equating to a saving of £1.4 million across the Yorkshire and Humber region.
Richard Stubbs, Chief Executive Officer at Yorkshire & Humber AHSN, said: “We are really proud of the work we have done to support this innovative test that is not only improving the experience of patients but also ensuring that precious NHS resources are optimised.
“I’m delighted that this has resulted in been shortlisted for the HSJ Award.”
The Yorkshire & Humber AHSN team and Dr James Turvill will find out if they have been successful in winning the Acute, Community or Primary Care Services Redesign HSJ Award on Wednesday 22 November at a ceremony to be held at the InterContinental O2, London.
In March this year, the Faecal Calprotectin programme was awarded a Medipex NHS Innovation Award.